{"id":60013,"date":"2026-06-04T22:55:41","date_gmt":"2026-06-04T13:55:41","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4582\/"},"modified":"2026-08-23T12:34:40","modified_gmt":"2026-08-23T03:34:40","slug":"company-4582","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4582\/","title":{"rendered":"SYMBIO PHARMACEUTICALS LTD"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4582","DATE":"2026-01-09","longName":"SymBio Pharmaceuticals Limited","company_name_ja":"","fullTimeEmployees":91,"address":"","phone":"","website":"https:\/\/www.symbiopharma.com","industry":"Drug Manufacturers - Specialty & Generic","sector":"Healthcare","regularMarketPrice":91,"financialCurrency":"","marketCap":4437,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-95.120000000000005,"epsForward":0,"bookValue":0,"totalRevenue":1307648000,"OperatingIncome":-4440688000,"operatingMargins":-339.58999999999997,"NetIncome":-4776194000,"profitMargins":-365.25,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-375.48000000000002,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T01:57:45.296921\", \"ticker\": \"4582\", \"ticker_full\": \"4582.T\", \"company_name\": \"SYMBIO PHARMACEUTICALS LTD\", \"company_info\": {\"name_en\": \"SYMBIO PHARMACEUTICALS LTD\", \"long_name\": \"SymBio Pharmaceuticals Limited\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - Specialty & Generic\", \"website\": \"https:\/\/www.symbiopharma.com\", \"employees\": 91, \"country\": \"Japan\", \"city\": \"Minato\", \"address\": \"Toranomon Towers Office\", \"description\": \"SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 68.2, \"deviation\": -4.69, \"trend\": \"down\"}, \"ma_25\": {\"ma_value\": 69.24, \"deviation\": -6.12, \"trend\": \"down\"}, \"ma_75\": {\"ma_value\": 73.29, \"deviation\": -11.32, \"trend\": \"down\"}, \"ma_200\": {\"ma_value\": 93.31, \"deviation\": -30.34, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 1307648000.0, \"revenue_fmt\": \"\u00a513\u5104\", \"gross_profit\": 947339000.0, \"gross_profit_fmt\": \"\u00a59\u5104\", \"operating_income\": -4440688000.0, \"operating_income_fmt\": \"-\u00a544\u5104\", \"ebit\": -4709450000.0, \"ebit_fmt\": \"-\u00a547\u5104\", \"net_income\": -4776194000.0, \"net_income_fmt\": \"-\u00a548\u5104\", \"eps\": -95.12, \"operating_margin\": -339.59, \"total_assets\": 3867316000.0, \"total_assets_fmt\": \"\u00a539\u5104\", \"total_equity\": 1272039000.0, \"total_equity_fmt\": \"\u00a513\u5104\", \"total_debt\": 1982500000.0, \"total_debt_fmt\": \"\u00a520\u5104\", \"total_cash\": 2883503000.0, \"total_cash_fmt\": \"\u00a529\u5104\", \"equity_ratio\": 32.89, \"de_ratio\": 1.56, \"current_ratio\": 2.96, \"operating_cf\": -4575568000.0, \"operating_cf_fmt\": \"-\u00a546\u5104\", \"investing_cf\": -75916000.0, \"investing_cf_fmt\": \"-\u00a575.9M\", \"financing_cf\": 3621610000.0, \"financing_cf_fmt\": \"\u00a536\u5104\", \"free_cf\": -4658040000.0, \"free_cf_fmt\": \"-\u00a547\u5104\", \"net_margin\": -365.25, \"roe\": -375.48, \"roa\": -123.5}, {\"year\": 2024, \"revenue\": 2452912000.0, \"revenue_fmt\": \"\u00a525\u5104\", \"gross_profit\": 1873189000.0, \"gross_profit_fmt\": \"\u00a519\u5104\", \"operating_income\": -3876972000.0, \"operating_income_fmt\": \"-\u00a539\u5104\", \"ebit\": -3806957000.0, \"ebit_fmt\": \"-\u00a538\u5104\", \"net_income\": -3833480000.0, \"net_income_fmt\": \"-\u00a538\u5104\", \"eps\": -85.0, \"operating_margin\": -158.06, \"total_assets\": 4968333000.0, \"total_assets_fmt\": \"\u00a550\u5104\", \"total_equity\": 4197559000.0, \"total_equity_fmt\": \"\u00a542\u5104\", \"total_debt\": 0.0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 3963580000.0, \"total_cash_fmt\": \"\u00a540\u5104\", \"equity_ratio\": 84.49, \"de_ratio\": 0.0, \"current_ratio\": 6.43, \"operating_cf\": -3416518000.0, \"operating_cf_fmt\": \"-\u00a534\u5104\", \"investing_cf\": -3955000.0, \"investing_cf_fmt\": \"-\u00a54.0M\", \"financing_cf\": 708472000.0, \"financing_cf_fmt\": \"\u00a57\u5104\", \"free_cf\": -3463395000.0, \"free_cf_fmt\": \"-\u00a535\u5104\", \"net_margin\": -156.28, \"roe\": -91.33, \"roa\": -77.16}, {\"year\": 2023, \"revenue\": 5589708000.0, \"revenue_fmt\": \"\u00a556\u5104\", \"gross_profit\": 4411013000.0, \"gross_profit_fmt\": \"\u00a544\u5104\", \"operating_income\": -811668000.0, \"operating_income_fmt\": \"-\u00a58\u5104\", \"ebit\": -811668000.0, \"ebit_fmt\": \"-\u00a58\u5104\", \"net_income\": -1962817000.0, \"net_income_fmt\": \"-\u00a520\u5104\", \"eps\": -49.19, \"operating_margin\": -14.52, \"total_assets\": 8170243000.0, \"total_assets_fmt\": \"\u00a582\u5104\", \"total_equity\": 7209910000.0, \"total_equity_fmt\": \"\u00a572\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 6517007000.0, \"total_cash_fmt\": \"\u00a565\u5104\", \"equity_ratio\": 88.25, \"de_ratio\": 0.0, \"current_ratio\": 8.45, \"operating_cf\": -194685000.0, \"operating_cf_fmt\": \"-\u00a52\u5104\", \"investing_cf\": -376696000.0, \"investing_cf_fmt\": \"-\u00a54\u5104\", \"financing_cf\": 680160000.0, \"financing_cf_fmt\": \"\u00a57\u5104\", \"free_cf\": -427482000.0, \"free_cf_fmt\": \"-\u00a54\u5104\", \"net_margin\": -35.11, \"roe\": -27.22, \"roa\": -24.02}, {\"year\": 2022, \"revenue\": 10008338000.0, \"revenue_fmt\": \"\u00a5100\u5104\", \"gross_profit\": 7599904000.0, \"gross_profit_fmt\": \"\u00a576\u5104\", \"operating_income\": 1963626000.0, \"operating_income_fmt\": \"\u00a520\u5104\", \"ebit\": 1963626000.0, \"ebit_fmt\": \"\u00a520\u5104\", \"net_income\": 1179238000.0, \"net_income_fmt\": \"\u00a512\u5104\", \"eps\": 29.77, \"operating_margin\": 19.62, \"total_assets\": 10433347000.0, \"total_assets_fmt\": \"\u00a5104\u5104\", \"total_equity\": 8506091000.0, \"total_equity_fmt\": \"\u00a585\u5104\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 6282554000.0, \"total_cash_fmt\": \"\u00a563\u5104\", \"equity_ratio\": 81.53, \"de_ratio\": 0.0, \"current_ratio\": 4.84, \"operating_cf\": 1614241000.0, \"operating_cf_fmt\": \"\u00a516\u5104\", \"investing_cf\": -47127000.0, \"investing_cf_fmt\": \"-\u00a547.1M\", \"financing_cf\": 627985000.0, \"financing_cf_fmt\": \"\u00a56\u5104\", \"free_cf\": 1566683000.0, \"free_cf_fmt\": \"\u00a516\u5104\", \"net_margin\": 11.78, \"roe\": 13.86, \"roa\": 11.3}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-60013","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SYMBIO PHARMACEUTICALS LTD - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4582\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/\",\"name\":\"SYMBIO PHARMACEUTICALS LTD - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:55:41+00:00\",\"dateModified\":\"2026-08-23T03:34:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4582\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4582\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SYMBIO PHARMACEUTICALS LTD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SYMBIO PHARMACEUTICALS LTD - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4582\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/","url":"https:\/\/japanir.jp\/en\/company\/company-4582\/","name":"SYMBIO PHARMACEUTICALS LTD - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:55:41+00:00","dateModified":"2026-08-23T03:34:40+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4582\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4582\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"SYMBIO PHARMACEUTICALS LTD"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/60013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=60013"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=60013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}